Environmental

Zoetis’ R&D intensity supports lower environmental footprint per revenue than many animal-health peers, because innovation can shift demand toward higher-value, lower-material-intensity products.

The company’s business model is less exposed to heavy manufacturing emissions than diversified healthcare peers, which structurally reduces energy and waste-management burdens.

No major environmental controversy is evident in the provided data, so its relative ESG position appears stable versus peers despite normal pharmaceutical supply-chain impacts.

Environmental risk remains material through packaging, sourcing, and regulated production, but these factors are typically less severe than at more resource-intensive healthcare manufacturers.

Social

Zoetis’ animal-health focus supports a favorable social profile versus human-pharma peers, because its products are tied to food security, pet health, and veterinary outcomes.

The company’s high gross margin and modest stock-based compensation suggest less pressure on labor relations and incentive alignment than peers with more aggressive compensation structures.

R&D spending at a meaningful share of revenue indicates continued investment in product safety and efficacy, which is important for trust and regulatory acceptance.

Social risk is still present through product quality, access, and responsible marketing, but these issues appear manageable relative to broader healthcare peers.

Governance

Zoetis’ stock-based compensation remains low relative to revenue, which supports governance quality versus peers with heavier dilution and weaker pay discipline.

Moderate leverage is manageable for the sector and does not indicate the balance-sheet stress that often weakens governance oversight at more levered peers.

Sustained R&D investment suggests board support for long-term innovation, which is a positive governance signal in a regulated life-sciences business.

The main governance constraint is that leverage is not minimal, so capital allocation discipline must remain stronger than at peers with cleaner balance sheets.

Overall Score

Zoetis ranks as a strong ESG performer versus peers, led by favorable social and governance characteristics and a comparatively manageable environmental footprint.

Score Driver: Its Animal-Health Business Model Creates A Structurally Lighter ESG Burden Than Many Healthcare Peers, While Compensation Discipline And R&D Support Reinforce The Profile.